156 related articles for article (PubMed ID: 22119956)
1. Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy.
Huang Z; Zhang Z; Jiang Y; Zhang D; Chen J; Dong L; Zhang J
J Control Release; 2012 Mar; 158(2):286-92. PubMed ID: 22119956
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of let-7b to reprogramme tumor-associated macrophages and tumor infiltrating dendritic cells for tumor rejection.
Huang Z; Gan J; Long Z; Guo G; Shi X; Wang C; Zang Y; Ding Z; Chen J; Zhang J; Dong L
Biomaterials; 2016 Jun; 90():72-84. PubMed ID: 26994345
[TBL] [Abstract][Full Text] [Related]
3. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
4. Target delivery selective CSF-1R inhibitor to tumor-associated macrophages via erythrocyte-cancer cell hybrid membrane camouflaged pH-responsive copolymer micelle for cancer immunotherapy.
Wang Y; Luan Z; Zhao C; Bai C; Yang K
Eur J Pharm Sci; 2020 Jan; 142():105136. PubMed ID: 31704343
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma.
Fan QM; Jing YY; Yu GF; Kou XR; Ye F; Gao L; Li R; Zhao QD; Yang Y; Lu ZH; Wei LX
Cancer Lett; 2014 Oct; 352(2):160-8. PubMed ID: 24892648
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Associated Macrophages as Target for Antitumor Therapy.
Sawa-Wejksza K; Kandefer-Szerszeń M
Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):97-111. PubMed ID: 28660349
[TBL] [Abstract][Full Text] [Related]
7. Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy.
Zhan X; Jia L; Niu Y; Qi H; Chen X; Zhang Q; Zhang J; Wang Y; Dong L; Wang C
Biomaterials; 2014 Dec; 35(38):10046-57. PubMed ID: 25245263
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma.
Degroote H; Van Dierendonck A; Geerts A; Van Vlierberghe H; Devisscher L
J Immunol Res; 2018; 2018():7819520. PubMed ID: 30410942
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers.
Huang Z; Yang Y; Jiang Y; Shao J; Sun X; Chen J; Dong L; Zhang J
Biomaterials; 2013 Jan; 34(3):746-55. PubMed ID: 23107297
[TBL] [Abstract][Full Text] [Related]
10. Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide.
Lee C; Jeong H; Bae Y; Shin K; Kang S; Kim H; Oh J; Bae H
J Immunother Cancer; 2019 Jun; 7(1):147. PubMed ID: 31174610
[TBL] [Abstract][Full Text] [Related]
11. Polarization of tumor-associated macrophage phenotype via porous hollow iron nanoparticles for tumor immunotherapy in vivo.
Li K; Lu L; Xue C; Liu J; He Y; Zhou J; Xia Z; Dai L; Luo Z; Mao Y; Cai K
Nanoscale; 2020 Jan; 12(1):130-144. PubMed ID: 31799577
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated macrophages: implications in cancer immunotherapy.
Petty AJ; Yang Y
Immunotherapy; 2017 Mar; 9(3):289-302. PubMed ID: 28231720
[TBL] [Abstract][Full Text] [Related]
13. Terminating the renewal of tumor-associated macrophages: A sialic acid-based targeted delivery strategy for cancer immunotherapy.
Ding J; Zhao D; Hu Y; Liu M; Liao X; Zhao B; Liu X; Deng Y; Song Y
Int J Pharm; 2019 Nov; 571():118706. PubMed ID: 31593811
[TBL] [Abstract][Full Text] [Related]
14. Progress in tumor-associated macrophage (TAM)-targeted therapeutics.
Ngambenjawong C; Gustafson HH; Pun SH
Adv Drug Deliv Rev; 2017 May; 114():206-221. PubMed ID: 28449873
[TBL] [Abstract][Full Text] [Related]
15. Local delivery of recombinant adenovirus expressing hepatitis B virus X protein and interleukin-12 results in antitumor effects via inhibition of hepatoma cell growth and intervention of tumor microenvironment.
He H; Fan P; Yin T; Chen Q; Shi H; Liu S; Li H; Jing Q; Yan Y; Zhang H; Yang L; Wen Y; Li Y; Cheng P
Int J Mol Med; 2012 Sep; 30(3):599-605. PubMed ID: 22710287
[TBL] [Abstract][Full Text] [Related]
16. Targeted Delivery of miRNA 155 to Tumor Associated Macrophages for Tumor Immunotherapy.
Zang X; Zhang X; Zhao X; Hu H; Qiao M; Deng Y; Chen D
Mol Pharm; 2019 Apr; 16(4):1714-1722. PubMed ID: 30860846
[TBL] [Abstract][Full Text] [Related]
17. "Layer peeling" co-delivery system for enhanced RNA interference-based tumor associated macrophages-specific chemoimmunotherapy.
Wang T; Mu W; Li F; Zhang J; Hou T; Pang X; Yin X; Zhang N
Nanoscale; 2020 Aug; 12(32):16851-16863. PubMed ID: 32761008
[TBL] [Abstract][Full Text] [Related]
18. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
19. Targeting tumor associated macrophages (TAMs) via nanocarriers.
Singh Y; Pawar VK; Meher JG; Raval K; Kumar A; Shrivastava R; Bhadauria S; Chourasia MK
J Control Release; 2017 May; 254():92-106. PubMed ID: 28377038
[TBL] [Abstract][Full Text] [Related]
20. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages.
Movahedi K; Schoonooghe S; Laoui D; Houbracken I; Waelput W; Breckpot K; Bouwens L; Lahoutte T; De Baetselier P; Raes G; Devoogdt N; Van Ginderachter JA
Cancer Res; 2012 Aug; 72(16):4165-77. PubMed ID: 22719068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
